Lipocine Inc. Files 8-K

Ticker: LPCN · Form: 8-K · Filed: Feb 11, 2025 · CIK: 1535955

Lipocine Inc. 8-K Filing Summary
FieldDetail
CompanyLipocine Inc. (LPCN)
Form Type8-K
Filed DateFeb 11, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: LPCN

TL;DR

Lipocine filed a routine 8-K, no major news yet.

AI Summary

Lipocine Inc. filed an 8-K on February 11, 2025, reporting other events and financial statements. The filing does not contain specific details about new events, material agreements, or financial results within the provided text, but indicates a standard regulatory filing.

Why It Matters

This filing indicates Lipocine Inc. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without disclosing specific material events, suggesting no immediate new risks.

Key Players & Entities

  • Lipocine Inc. (company) — Registrant
  • February 11, 2025 (date) — Date of Report
  • 675 Arapeen Drive, Suite 202 (address) — Principal executive offices
  • Salt Lake City, Utah 84108 (address) — Principal executive offices
  • 001-36357 (company_id) — Commission File Number

FAQ

What specific 'Other Events' are being reported by Lipocine Inc. in this 8-K filing?

The provided text for the 8-K filing indicates 'Other Events' as an item information, but does not specify the nature of these events.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted on February 11, 2025.

What is the principal executive office address for Lipocine Inc.?

The principal executive office address for Lipocine Inc. is 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is Lipocine Inc.'s Commission File Number?

Lipocine Inc.'s Commission File Number is 001-36357.

Does this filing include any new financial statements or exhibits?

Yes, the filing is categorized under 'Financial Statements and Exhibits', indicating that such documents are included, though their specific content is not detailed in the provided text.

Filing Stats: 411 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-02-11 09:00:16

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: February 11, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.